ClinicalTrials.gg
RecruitingNCT06958705Updated Nov 25, 2025

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

A Phase 2 interventional study of Venetoclax combined with Ibrutinib and Venetoclax combined with Zanubrutinib in Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
33rd of 69
79 · median 72
Started
2025
with 4 others
Phase 2
41 of 69
16 open now
Primary completion
2027-12
later than 26 of 41 live
Registered
61st of 69
by date

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 33rd largest by planned enrollment, is one of 5 that started in 2025, is one of 41 in phase 2, reaches primary completion later than 26 of the 41 other live ones, and was the 61st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase 2, non-randomized study aiming to study the efficacy and safety of fixed-duration venetoclax consolidation in CLL patients who are on BTK inhibitor monotherapy. Patients who are on BTK inhibitor monotherapy for ≥ 6 months and still responsive are included. The study includes patients who are treatment-naive before taking BTK inhibitors. Patients will be treated with the BTK inhibitor plus full-dose venetoclax for 12 cycles after a standard 5-week dose ramp-up. Peripheral blood and bone marrow MRD status will be evaluated during and after the treatment. After the completion of combination therapy, patients will stop both BTK inhibitor and venetoclax and be followed.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age: 18-80 years-old.
  • 2. Patients must have a diagnosis of CLL/SLL.
  • 3. Detectable MRD by flow cytometry (10\^-4 sensitivity) in the peripheral blood.
  • 4. Patients who are on BTK inhibitor monotherapy for more than 6 months. This study includes patients who are taking one of the following BTK inhibitors: ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib.
  • 5. Patients need to have a response of at least PR (CR/PR) to BTK inhibitor monotherapy.
  • 6. (ECOG) Performance Status ≤ 2.
  • 7. Patients must have adequate renal and hepatic function:
  • Serum ≤ 1.5 × (ULN) or ≤ 3 × ULN for patients with Gilbert's disease;
  • Serum of ≥ 50 ml/min (calculated or measured);
  • and AST ≤ 3.0 × ULN, unless clearly due to disease involvement.
  • 8. Adequate bone marrow function:
  • count of greater than 50,000/µl, with no platelet transfusion in prior 2 weeks;
  • ≥ 1000/µl in the absence of growth factor support unless due to compromised bone marrow production from CLL, indicated by ≥ 80% CLL in marrow;
  • ≥ 8g/dL.
  • 9. Adequate cardiac function, as assessed by:
  • Absence of uncontrolled cardiac arrhythmia;
  • Echocardiogram demonstrating ≥ 35%;
  • functional class ≤ 2.
  • 10. Ability to provide and adhere to the required follow-up.

Exclusion criteria

Exclusion Criteria:

  • 1. Richter transformation.
  • 2. Active requiring systemic therapy, other than CLL, with the exception of: adequately treated in situ carcinoma of the cervix uteri; adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  • 3. Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drug.
  • 4. Grade 3 or 4 hemorrhage within the past 3 weeks.
  • 5. Uncontrolled active infections (viral, bacterial, and fungal).
  • 6. Females who are pregnant or lactating.
  • 7. Known positive.
  • 8. Active infection (defined as the presence of detectable HBV DNA or HBe antigen). Patients who are HBsAg positive or HBcAb positive are eligible, provided HBV DNA is negative. These patients must have monthly monitoring of HBV DNA for the duration of the study.
  • 9. Active , defined by the detection of hepatitis C RNA in plasma by PCR.
  • 10. Active, uncontrolled phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring therapy > 20 mg prednisone daily or equivalent, within 7 days of starting venetoclax.
  • 11. Received other therapeutic agents for CLL/SLL during BTK inhibitor treatment prior to enrollment.
  • 12. Concurrent use of warfarin or equivalent vitamin K inhibitor or other oral anticoagulant treatment.
  • 13. Received strong inhibitors or strong CYP3A inducers within 7 days of starting venetoclax.
  • 14. Consuming grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting venetoclax.
  • 15. Prior treatment with venetoclax or other Bcl-2 inhibitor.
  • 16. Malabsorption syndrome or other condition that precludes enteral route of administration.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (estimated)

Study arms

  • Experimental
    CLL/SLL patients on ibrutinib monotherapy for ≥ 6 months

    Drug: Venetoclax combined with Ibrutinib

  • Experimental
    CLL/SLL patients on zanubrutinib monotherapy for ≥ 6 months

    Drug: Venetoclax combined with Zanubrutinib

  • Experimental
    CLL/SLL patients on acalabrutinib monotherapy for ≥ 6 months

    Drug: Venetoclax combined with Acalabrutinib

  • Experimental
    CLL/SLL patients on orelabrutinib monotherapy for ≥ 6 months

    Drug: Venetoclax combined with Orelabrutinib

Interventions

  • DrugVenetoclax combined with Ibrutinib

    Drug pages: VenetoclaxStudies of VenetoclaxVenetoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IbrutinibStudies of IbrutinibIbrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using ibrutinib. After the completion of combination therapy, patients will stop both the ibrutinib and venetoclax then be followed. Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and ibrutinib will continue for an additional 12 cycles. Venetoclax and ibrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first. Ibrutinib is intended to be admistratered orally 420mg once daily.

  • DrugVenetoclax combined with Zanubrutinib

    Drug pages: VenetoclaxStudies of VenetoclaxVenetoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ZanubrutinibStudies of ZanubrutinibZanubrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using zanubrutinib. After the completion of combination therapy, patients will stop both the zanubrutinib and venetoclax then be followed. Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and zanubrutinib will continue for an additional 12 cycles. Venetoclax and zanubrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first. Zanubrutinib is intended to be admistratered orally 160mg twice daily.

  • DrugVenetoclax combined with Acalabrutinib

    Drug pages: VenetoclaxStudies of VenetoclaxVenetoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AcalabrutinibStudies of AcalabrutinibAcalabrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using acalabrutinib. After the completion of combination therapy, patients will stop both the acalabrutinib and venetoclax then be followed. Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and acalabrutinib will continue for an additional 12 cycles. Venetoclax and acalabrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first. Acalabrutinib is intended to be admistratered orally 100mg twice daily.

  • DrugVenetoclax combined with Orelabrutinib

    Drug pages: VenetoclaxStudies of VenetoclaxVenetoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · OrelabrutinibStudies of OrelabrutinibOrelabrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using orelabrutinib. After the completion of combination therapy, patients will stop both the orelabrutinib and venetoclax then be followed. Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and orelabrutinib will continue for an additional 12 cycles. Venetoclax and orelabrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first. Orelabrutinib is intended to be admistratered orally 150mg once daily.

06

What researchers measure

Primary outcomes

  1. Rate of BM-uMRD after completion of combination therapy (Day 1 of Cycle 16)

    Rate of BM-uMRD is defined by negative MRD in the bone marrow by flow cytometry at a sensitivity of 10\^-4. The Clopper Pearson method is used to estimate the 95% two-sided confidence interval (CI) of the rate of BM-uMRD.

    Time frame: On Day 1 of Cycle 16 (each cycle is 28 days)

Secondary outcomes

  1. Rate of undetected peripheral blood MRD by flow cytometry

    Rate of undetected peripheral blood MRD is defined by negative MRD in the peripheral blood by flow cytometry at a sensitivity of 10\^-4.

    Time frame: On screening, Day 1 of Cycle 4, Day 1 of Cycle 7, Day 1 of Cycle 10, Day 1 of Cycle 16, Day 1 of Cycle 20, Day 1 of Cycle 24, Day 1 of Cycle 28 and Day 1 of Cycle 34 (each cycle is 28 days)

  2. Rate of complete response (CR)

    CR is defined by the 2018 IWCLL criteria. Enhanced contrast CT combined with bone marrow examination will be performed to determine if a patient achieve CR.

    Time frame: On Day 1 of Cycle 7, Day 1 of Cycle 16, Day 1 of Cycle 22, and Day 1 of Cycle 28 (each cycle is 28 days)

  3. Progression-free survival (PFS)

    PFS is defined as the time from the first dose of venetoclax to progression, or death due to any cause, whichever occurs first. For subjects without progression, relapse, or death at the time of analysis, EFS will be censored at the last assessment date.

    Time frame: From the first dose of venetoclax until the date of progression or date of death from any cause, whichever came first, assessed up to 112 months

  4. Overall survival (OS)

    OS is defined as the time from the first dose of venetoclax to death due to any cause. Subjects who remain alive at the time of analysis will be censored at the last known alive date of the subject.

    Time frame: From the first dose of venetoclax until the date of death from any cause, assessed up to 112 months

  5. Time to next treatment (TTNT)

    TTNT is defined as the time from the first dose of venetoclax to the next CLL-directed therapies.

    Time frame: From the first dose of venetoclax to the next CLL-directed therapies due to progression, assessed up to 112 months

  6. Adverse Events

    All treatment-emergent AEs will be included in the analysis. For each AE, the number and percentage of subjects who experience at least one occurrence of the given event will be summarized. The number and percent of subjects with TEAEs will be summarized according to intensity (CTCAE, v5) or IWCLL for hematologic toxicity, and drug relationship, as well as categorized by system organ class and preferred term. Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those subjects who die, who discontinue treatment due to an AE, or who experience a severe AE or a SAE.

    Time frame: From screening to 30 days after the end of cycle 12 (each cycle is 28 days)

Other outcomes

  1. MRD relapse

    MRD relapse is now defined as either: (1) conversion of MRD negativity to MRD positivity, independent of the MRD technique, or (2) increase of MRD ≥ 1 log10 between any 2 positive samples measured in the same tissue (PB or BM) in patients with MRD+ CLL.

    Time frame: From the date of MRD negativity to the date of MRD positivity or the occurrence of increase of MRD ≥ 1 log10 between any 2 positive samples measured in the same tissue, assessed up to 112 months

  2. Clearance of BTK C481S mutation

    Baseline BTK C418S mutation by droplet digital PCR will performed. Patients with detected baseline BTK C481S mutation will be re-evaluated at C4D1, C7D1, C10D1, and C16D1 to determine the effects of venetoclax on the clearance of BTK C481S mutation.

    Time frame: On Day 1 of Cycle 4, Day 1 of Cycle 7, Day 1 of Cycle 10, and Day 1 of Cycle 16 (each cycle is 28 days)

  3. Occurance of laboratory or clinical TLS

    In the dose ramp-up phase, laboratory and clinical monitoring will be regularly performed to determine if TLS occur.

    Time frame: From Day 1 of Cycle 0 to Day 28 of Cycle 0 (dose ramp-up phase)

  4. MRD level detected by NGS IG sequencing

    Peripheral blood MRD by NGS of immunoglobulin (IG) will be evaluated at C0D1, C4D1, C7D1, C10D1, and C16D1. NGS of IG for determining bone marrow MRD status will be performed at C0D1, C7D1, and C16D1. At the timepoints, the correlation between MRD by flow cytometry and NGS MRD will be evaluated.

    Time frame: On Day 1 of Cycle 0, Day 1 of Cycle 4, Day 1 of Cycle 7, Day 1 of Cycle 10, and Day 1 of Cycle 16 (each cycle is 28 days)

07

Study locations

1 of 1 sites recruiting
  • Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Jianyong Li, PhD, MD · Contactlijianyonglm@126.com · 86-13951877733
    • Huayuan Zhu, PhD, MD · Contacthuayuan.zhu@hotmail.com · 86-13813810650
    • Jianyong Li, PhD, MD · Principal investigator
    • Huayuan Zhu, PhD, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2027, 24 months later.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 24 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
May 6, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Feb 1, 2028
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06958705
Collaborators
AbbVie
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Nov 25, 2025

Study contacts

Jianyong Li, PhD, MD
Contact
lijianyonglm@126.com
86-13951877733
Huayuan Zhu, PhD, MD
Contact
huayuan.zhu@hotmail.com
86-13813810650

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Ibrutinib · Zanubrutinib · Acalabrutinib · Orelabrutinib

Start the discussion